

# **UPDATE Executive Officer Notice: Reimbursement and Claim Submissions for Mifepristone / Misoprostol Products**

**April 23, 2026**

This is an update to the original Executive Officer (“EO”) notice dated [August 3, 2017](#) (updated on December 7, 2017) regarding the reimbursement and claim submissions for mifepristone/misoprostol products. Since [August 2017](#), Ontario has publicly funded Mifegymiso<sup>®</sup> (mifepristone/misoprostol) for all Ontarians with:

- a valid Ontario health card number, and
- a valid prescription.

Effective April 30, 2026, Femyso<sup>™</sup> (mifepristone/misoprostol), a generic version of mifepristone/misoprostol, will be designated as an Off-Formulary (OFI) interchangeable product with Mifegymiso<sup>®</sup> under the *Drug Interchangeability and Dispensing Fee Act* (DIDFA) and will be eligible for public funding in accordance with this EO notice.

## **Reimbursement Amount for Mifepristone/Misoprostol Products**

For each valid claim for payment (“claim”) submitted in accordance with this EO notice, pharmacies will be paid a professional service fee, which consists of the applicable drug cost (i.e., unit price) of the product dispensed, a mark-up on that price, and a dispensing fee. The total reimbursement amount for a valid claim is set out in Table 1 below.

The unit price of publicly funded mifepristone/misoprostol products will follow the [pan-Canadian Tiered Pricing Framework](#). Please refer to the [Ontario Drug Benefit \(ODB\) Formulary / Comparative Drug Index \(CDI\)](#) for the unit price.

## **Patient Eligibility**

There have been no changes to patient eligibility for publicly funded mifepristone/misoprostol products. All Ontarians with a valid Ontario health card number and a valid prescription are eligible for publicly funded mifepristone/misoprostol products (“eligible patients”). This includes ODB-eligible and non-ODB-eligible recipients.

## **Pharmacy Eligibility and Documentation Requirements**

All pharmacies with valid Health Network System (HNS) subscription agreements and that are connected to the HNS may submit claims for payment for supplying publicly funded mifepristone/misoprostol products to eligible patients. Pharmacists who have a religious or conscientious objection to mifepristone/ misoprostol products are required to comply with any policies or other professional expectations set out by the Ontario College of Pharmacists (OCP), such as the [Human Rights Policy](#).

Standard documentation requirements for prescriptions apply. Pharmacists must keep records consistent with their obligations under the *Pharmacy Act, 1991*, the *Drug and Pharmacies Regulation Act (DPRA)*, and any further instructions provided by the OCP and the Ministry of Health (ministry).

For the purposes of post-payment verification and in accordance with O. Reg. 264/16 made under the DPRA if applicable, records must be maintained for the Retention Period, as defined in the [Ontario Drug Programs Reference Manual](#) as “a period of at least 10 years from the last recorded pharmacy service provided to the ODB recipient, or 10 years after the day on which the ODB recipient reached or would have reached the age of 18 years, whichever is longer”.

## **Pharmacy Billing Procedure**

The mifepristone/misoprostol products listed in Table 1 below, when supplied to eligible patients and supported by a valid claim, will be reimbursed by the ministry.

- The Drug Identification Numbers (DINs) that appear in the Product Description column are used to differentiate between the publicly funded mifepristone/misoprostol products and will appear on the OFI to facilitate the interchangeability of the products.
- The PINs are to be used by pharmacies when submitting claims to the ministry. Each PIN is associated with a reimbursement amount that will be paid for each valid claim. The reimbursement amount consists of the applicable drug cost (i.e., unit price) of the product dispensed, a mark-up on that price, and a dispensing fee.

The ministry will accept manual/ paper claims for publicly funded mifepristone/misoprostol products if there is a need to use three intervention codes.

Table 1:

PIN	Product Description (DIN)	Reimbursement amount
09858391	Mifegymiso® (02444038)	\$256.2500
09858392	Femyso™ (02560569)	\$256.2500

When submitting electronic claims via the HNS, pharmacies must ensure the eligible patient’s correct date of birth, health number and name (as it appears on the Ontario Health Card) are entered accurately. Failure to do so may impact a pharmacy’s ability to submit future claims for these individuals.

**ODB-Eligible Patients**

When submitting a claim for an eligible patient who has ODB program coverage, pharmacies must follow the normal process for submitting claims on the HNS with the following additional information:

- Intervention code *PS: Professional Care Services*
- Product Identification Number (PIN): 09858391 or 09858392
- Valid Pharmacist ID
- Professional Fee: **\$256.2500** (includes drug cost, mark-up and dispensing fee)

**Non-ODB-Eligible Patients**

When submitting a claim for an eligible patient who does not have ODB program coverage, pharmacies must submit the following information:

- Patient Gender: ‘F’ = female; ‘M’ = male
- Patient Date of Birth: YYYYMMDD
- Patient’s Ontario Health Card number
- Intervention codes:
  - PS: Professional Care Services
  - ML: Established eligibility coverage (i.e., 1 day of the Plan ‘S’ coverage)
- Carrier ID: ‘S’
- Product Identification Number (PIN): 09858391 or 09858392
- Valid Pharmacist ID
- Professional Fee: **\$256.2500** (includes drug cost, mark-up and dispensing fee)

### **Ministry Policy**

The original EO notice dated August 3, 2017 and any updates to the EO notice are a ministry policy that pharmacy operators must comply with under section 3.2 of the HNS Subscription Agreement for Pharmacy Operators.

### **Additional Information**

#### **For pharmacies:**

For billing inquiries, please call ODB Pharmacy Help Desk at: 1-800-668-6641

#### **For all other Health Care Providers and the Public:**

Please call ServiceOntario, Infoline at 1-866-532-3161 TTY 1-800-387-5559. In Toronto, TTY 416-327-4282

All other inquiries regarding the policy should be directed to:

[DrugProgramsDelivery@ontario.ca](mailto:DrugProgramsDelivery@ontario.ca)